This site is for U.S. Healthcare Professionals only.
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Poster
I-DXd
WCLC 2025 | September 6-9 2025
A phase 1b/2 study of gocatamig and ifinatamab deruxtecan for relapsed or refractory extensive-stage small cell lung cancer
Poster
T-DXd
WCLC 2025 | September 6-9 2025
Concordance of HER2 overexpression by IHC and ERBB2 gene amplification by NGS in lung cancer
Oral
I-DXd
WCLC 2025 | September 6-9 2025
Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer: Primary analysis of the phase 2 IDeate-Lung01 study
Oral
Dato-DXd
WCLC 2025 | September 6-9 2025
Intracranial efficacy of datopotamab deruxtecan (Dato‑DXd) in patients with advanced/metastatic NSCLC in TROPION-Lung01
Poster
T-DXd
WCLC 2025 | September 6-9 2025
Osimertinib treatment increases expression of HER2 and combination treatment with trastuzumab deruxtecan, a HER2-directed antibody-drug conjugate, enhances its efficacy in PDX models of EGFR mutant non small-cell lung cancer
Oral
Dato-DXd
WCLC 2025 | September 6-9 2025
Real-world assessment of TROP2 NMR by quantitative continuous scoring (QCS) in non-small cell lung carcinoma (NSCLC)
Poster
T-DXd
WCLC 2025 | September 6-9 2025
Trastuzumab deruxtecan + pembrolizumab as first-line treatment in HER2-overexpressing, PD-L1 TPS <50% NSCLC (DESTINY-Lung06)
Poster
T-DXd
WCLC 2025 | September 6-9 2025
Trastuzumab deruxtecan in patients from China with pretreated HER2-mutant NSCLC: Final results from the DESTINY-Lung05 study